Axsome Settling Teva Patent Litigation Is Another Positive Catalyst -- UpgradeSeeking Alpha • 02/11/25
Earnings Preview: Axsome Therapeutics (AXSM) Q4 Earnings Expected to DeclineZacks Investment Research • 02/11/25
Axsome (AXSM) Surges 20.2%: Is This an Indication of Further Gains?Zacks Investment Research • 02/11/25
Axsome Therapeutics Resolves Generic Patent Litigation With Teva Over Depression Drug, Analyst Maintains Axsome As 'Top Pick For 2025'Benzinga • 02/10/25
Axsome Therapeutics Hosts SYMBRAVO® FDA Approval Virtual Investor Event with Expert Thought LeaderGlobeNewsWire • 01/31/25
Axsome Therapeutics Announces FDA Approval of SYMBRAVO® (meloxicam and rizatriptan) for the Acute Treatment of Migraine with or without Aura in AdultsGlobeNewsWire • 01/30/25
Axsome Reveals Data From Alzheimer's Studies, Analyst Sees Hope Despite Mixed Trial ResultsBenzinga • 12/31/24
Axsome Flashes A Bearish Signal On Mixed Results In Alzheimer's AgitationInvestors Business Daily • 12/30/24
Axsome Therapeutics, Tesla And Other Big Stocks Moving Lower In Monday's Pre-Market SessionBenzinga • 12/30/24
Axsome's drug for Alzheimer's disease agitation meets main goal in late-stage studyReuters • 12/30/24
Axsome Therapeutics Announces Successful Completion and Results of Phase 3 Clinical Program of AXS-05 in Alzheimer's Disease AgitationGlobeNewsWire • 12/30/24
Axsome: Focus On AXS-12 Targeting Narcolepsy, Which Just Released Positive DataSeeking Alpha • 11/29/24
Axsome Therapeutics' AXS-12 Data For Sleeping Disorder Boosts Confidence In Approval And Market Potential, Analyst SaysBenzinga • 11/27/24
Axsome's Q3 Earnings Beat, Auvelity Drives Sales Growth, Stock UpZacks Investment Research • 11/13/24